F.H. Investments Inc dba Asteria Health. Birmingham, AL. 483 issued 12/19/2025

Costa Mesa, California — February 13, 2026 — Green Lumber Holding, LLC (“Green Lumber”) is issuing an updated consumer alert regarding counterfeit products falsely marketed as genuine Green Lumber products that may pose potential health risks.

New legislation will be required for FDA to continue collecting biosimilar user fees in future fiscal years. Information related to FDA’s preparation for the third reauthorization of BsUFA will be hosted here on this page as it becomes available.

Opening Remarks by Sara Brenner, U.S. Food and Drug Administration
September 23, 2025

The FDA is alerting health care providers to the recall of certain VasoView HemoPro devices due to risk of silicone detachment during use, and supply concerns.

Since the passage of the Biosimilar User Fee Act (BsUFA) in 2012, user fees have played an important role in expediting the process for the review of biosimilar products.

On September 18 and 19, 2025, the U.S. Food and Drug Administration (FDA) is hosting a virtual public workshop to discuss methodological challenges related to patient experience data encountered, including the submission and evaluation of patient experience data in the context of the benefit-risk assessment and product labeling, as well as other ar